Diligent Announces Diligent AI to Empower Governance, Risk and Compliance Professionals to Better Manage and Respond to Risk
11.6.2024 15:00:00 EEST | Business Wire | Press release
Diligent, a leading GRC SaaS company, today announced Diligent AI, a powerful set of artificial intelligence capabilities within the Diligent One Platform that enhance how organizations understand, anticipate and mitigate risks. Diligent AI will enable users to identify risks, safeguard data and democratize the decision-making processes, driving resilience and empowering organizations with certainty and clarity like never before.
"Company leaders face a dynamic and evolving risk environment. It’s imperative to turn data into strategic intelligence to anticipate and prevent risks, rather than just respond to them,” said Brian Stafford, President and CEO of Diligent. “Diligent’s AI-enhanced platform is uniquely positioned to connect all aspects of governance, risk and compliance, delivering customized insights to elevate governance and clarify risk.”
Diligent AI helps leaders amplify critical insights while working together across the organization, using risk as a shared language. Leaders can expand resources and achieve greater results through integrated automation, enhance stakeholder communication by tailoring information to board members, chief financial officers, chief risk officers and other executives, and enhance decision making by breaking down information silos across governance, risk and compliance (GRC) functions.
Register for the first session in Diligent’s AI webinar series starting on June 13, where Diligent leaders and experts will discuss Diligent AI capabilities and how they:
Elevate Governance for Boards and Leaders:
- Creating efficient, context-aware summaries of board materials to help directors easily digest information and glean insights.
- Providing AI-powered insights into a company’s ESG focus and self-disclosed risk factors, enabling peer comparison and helping to identify industry trends.
- Quickly assisting with boards-related questions through a 24/7 AI-powered virtual assistant.
Clarify Risk for Audit, Risk and Compliance Teams:
- Simplifying the tedious process of mapping internal controls to regulatory requirements, enabling GRC professionals to efficiently demonstrate compliance.
- Identifying changes between two versions of the same regulation, categorizing them as significant, moderate or minor, enabling users to efficiently update related policies, risks and controls.
- Empowering users to create, edit and troubleshoot data integrations and data analytics scripts using plain language. This brings Diligent's powerful robotics capabilities (also known as ACL Analytics) to a broader audience.
Additional capabilities will be added to Diligent AI over the coming months that empower GRC professionals to better mitigate risks and stay on top of changing regulatory requirements, and help corporate directors govern more effectively amidst escalating risks and information overload.
“Diligent AI adds to the breadth of the Diligent One Platform by enabling leaders to more quickly and effectively respond to risk in a competitive environment,” said Phil Lim, Global AI Champion at Diligent. “Our thoughtful and ethical approach to AI use, guided by industry-leading principles, means customers can feel secure in knowing that AI interacts with their data safely and securely, and only with their prior consent.”
The use of Generative AI in GRC must uphold the highest standards of safety and security, and Diligent has committed to the safe, secure and ethical use of AI through its guiding principles. This ensures users’ data stays their own, generated content is clearly labelled and users must always opt-in before using AI with their data. Learn more about Diligent’s AI Principles here.
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611912292/en/
Contacts
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 19:27:00 EET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom